Scarica l'app Stockscreener
2.29
0.00%
0.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Veru Inc Borsa (VERU) Ultime notizie
Veru outlines Phase III plans for enobosarm and signals upcoming FDA clarity on lean mass preservation in obesity treatment - MSN
If You Invested $1,000 in Veru (VERU) - Stock Titan
Volume Recap: Is Veru Inc attractive for institutional investors2026 Volume & Weekly High Return Stock Forecasts - baoquankhu1.vn
Veru Inc. Amends 2018 Equity Incentive Plan and Reports Annual Meeting Results – Form 8-K Filing March 12, 2026 - Minichart
Veru Shareholders Expand Equity Plan, Reelect Board Leadership - The Globe and Mail
Veru (NASDAQ: VERU) investors back larger equity plan, board slate and auditor - Stock Titan
Aug Macro: Is Veru Inc attractive for institutional investors2026 Opening Moves & Daily Market Momentum Tracking - baoquankhu1.vn
Veru Inc. (NASDAQ: VERU) Q1 2026 earnings call transcript - MSN
Veru Targets GLP-1 Muscle Loss Risk With New Enobosarm Combo Study - TipRanks
Veru enrolls first patient in obesity drug combination trial By Investing.com - Investing.com Canada
Veru (VERU) Launches Phase 2b Trial for Obesity Treatment - GuruFocus
Veru enrolls first patient in Phase 2b PLATEAU trial of enobosarm - TipRanks
Veru enrolls first patient in obesity drug combination trial - Investing.com Australia
Veru Inc. Initiates Phase 2b Clinical Trial for Enobosarm to Enhance Weight Loss in Older Patients with Obesity Receiving Semaglutide - Quiver Quantitative
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss - Yahoo Finance
VERU Earnings History & Surprises | EPS & Revenue Results | VERU INC (NASDAQ:VERU) - ChartMill
Veru Inc. (VERU) Presents at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceSlideshow - Seeking Alpha
Veru : Corporate Presentation, February 2026 - marketscreener.com
VERU Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
VERU Should I Buy - Intellectia AI
Veru at Oppenheimer Conference: Strategic Insights into Obesity Drug Development - Investing.com
VERU PE Ratio & Valuation, Is VERU Overvalued - Intellectia AI
Aug Volume: Is CHGG vulnerable to short sellersJuly 2025 Volume & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget
Tootsie Roll among names set to join Russell 3000 Index, Growgeneration, Veru set to leave - Intellectia AI
Will Veru Inc. benefit from sector rotationWeekly Trend Summary & Long-Term Capital Growth Strategies - mfd.ru
Aug Closing: Can PIII outperform under higher oil pricesAnalyst Downgrade & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Earnings call transcript: Veru Inc. Q1 2026 sees stock rise amid strategic shifts - Investing.com Nigeria
Veru outlines new Phase IIb obesity trial and targets interim analysis in Q1 2027 while increasing cash reserves - MSN
Veru Q1 2026 earnings preview - MSN
Veru Inc. (NASDAQ:VERU) Q1 2026 Earnings Call Transcript - Insider Monkey
Veru Q1 2026 Earnings Call Transcript - MarketBeat
Veru Inc. Charts Risky but Clearer Post-GLP-1 Path - TipRanks
Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Veru Inc. (VERU) Advances Clinical Pipeline with Enobosarm and S - GuruFocus
Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Adva - GuruFocus
VERU INC. SEC 10-Q Report - TradingView
VERU: No revenue, $5.3M net loss, $33M cash, strategic shift to drug development, going concern risk - TradingView
Earnings call transcript: Veru Inc. Q1 2026 sees stock rise amid strategic shifts By Investing.com - Investing.com South Africa
Veru (VERU) Q1 2026 Earnings Call Transcript - The Globe and Mail
VERU: Net loss narrowed, cash reserves rose, and enobosarm advances with FDA support for new trials - TradingView
Veru reports Q1 EPS (26c) vs. (61c) last year - TipRanks
VERU INC (NASDAQ:VERU) Reports Narrower-Than-Expected Q1 Loss, Highlights Key Clinical Trial Timeline - ChartMill
Veru Inc. Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress - TradingView
VERU: Q1 net loss narrowed, cash rose, and new enobosarm/semaglutide trial to launch soon - TradingView
Veru (NASDAQ: VERU) narrows loss as enobosarm obesity program advances - Stock Titan
Veru Inc. Advances Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide for Weight Management in Older Adults with Obesity - Quiver Quantitative
Veru tests enobosarm to help older semaglutide users beat weight-loss plateau - Stock Titan
A Look at Veru's Upcoming Earnings Report - Benzinga
Veru (VERU) price target increased by 11.11% to 25.50 - MSN
Veru Inc. (VERU.US) is scheduled to release its earnings report before the market opens on February 11. - 富途牛牛
Veru (VERU) Price Target Increased by 11.11% to 25.50 - Nasdaq
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):